What does a semaglutide cycle for weight loss actually involve?

What does the step-up schedule look like from week one?

Wegovy's licensed escalation pathway begins at 0.25 mg once weekly. That dose is a tolerability starter, its job is to let your digestive system adapt to semaglutide, not to produce significant weight loss right away. From there, your prescriber steps you up in roughly four-weekly intervals through 0.5 mg, 1.0 mg and 1.7 mg before reaching the standard 2.4 mg maintenance dose. Most people reach that maintenance dose after around 16 to 20 weeks.

If side effects at any point are difficult to manage, a prescriber can hold at the current dose for longer before moving up. That flexibility is deliberate. Rushing the escalation to chase faster results tends to make nausea worse, not weight loss better. The mechanism behind semaglutide's effect on appetite relies on sustained exposure at therapeutic doses, so patience in the early weeks pays off later.

One practical note a lot of people find useful: if you want to understand how the semaglutide cycle is structured from start to finish, including what each phase involves and how long it typically lasts, that page is a helpful reference before you begin. Consistency in timing matters, and a simple routine removes the mental load of remembering.

Does semaglutide have a fixed end point, or does the cycle continue indefinitely?

This is one of the most common questions our prescribers hear. The honest answer is that current clinical guidance frames semaglutide as a medium-to-long-term treatment rather than a short course. NICE's appraisal of semaglutide for weight management (TA875) recommends use for a maximum of two years within a specialist weight management pathway on the NHS. In private settings the picture is less fixed, but the same principle applies: treatment duration is a clinical decision made with your prescriber, not a set-it-and-forget-it choice.

Crucially, NICE guidance indicates that if weight loss remains below 5% after six months at the highest tolerated dose, continuing the medicine should be reviewed. That built-in checkpoint is not a failure point, it is the system working as intended, making sure the treatment is delivering meaningful benefit before it continues. Your prescriber should be monitoring your progress at each stage of the cycle, which is why clinical re-review before every repeat matters at a properly run service.

Weight often creeps back after stopping semaglutide, which is well-documented in the trial literature. That does not mean treatment must run forever, but it does mean the long-term picture of semaglutide and weight is worth discussing honestly with your prescriber rather than treating the medicine as a fixed-length course with a neat finish line.

What should you expect during the maintenance phase of the cycle?

Once you reach your maintenance dose, the weekly injection continues at that level. For most people, 2.4 mg is the target; the recently approved 7.2 mg single-dose pen represents a higher maintenance option for eligible adults with obesity, following MHRA approval in April 2026. Whether a higher dose is appropriate is a clinical assessment, not a personal choice to make alone.

Side effects during maintenance are generally milder than during escalation. The gastrointestinal symptoms (nausea, loose stools, reflux) that tend to peak with dose increases often settle as the body adjusts. The NHS semaglutide medicines page has a clear overview of what to expect and which symptoms should prompt you to seek medical advice rather than wait them out. Severe, persistent abdominal pain that reaches the back warrants prompt attention and should not be ignored.

Appetite suppression during maintenance is where most of the meaningful weight loss happens. Protein intake, hydration and staying active all support the results, and your prescriber or a dietitian can give specific guidance tailored to you. For anyone still weighing up their options, our page on whether semaglutide can be used for weight loss covers the evidence and eligibility considerations in plain terms before you commit to a cycle.

Who can start a semaglutide weight-loss cycle, and what does the review process involve?

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. Ethnic-background thresholds can be 2.5 kg/m² lower under UK clinical guidance, your prescriber applies the right threshold for you. Age matters too: semaglutide is not licensed for under-18s, and it is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive.

At a regulated service, the review process before each stage of the cycle includes checking that you are tolerating the current dose, that your weight is being monitored, and that no new contraindications have emerged. That is not red tape, it is the clinical infrastructure that makes the cycle safe. You can check your eligibility and start a free consultation with our prescribers, who review every application personally. The Wegovy treatment page covers what to expect from the consultation itself, and our clinical team is available for aftercare seven days a week once treatment is under way.